Shots:
Visus to receive $15M up front, ~$115M in milestones along with royalties in licensed territories. ZKO will lead the clinical development, regulatory approval & commercialization activities for Brimochol PF & Carbachol PF in the territories
ZKO will use its clinical development experience while Visus supports the ongoing P-III studies & launch the product in Greater China, South Korea & selected Southeast Asian markets
ZKO continues to expand its pipeline of ophthalmic assets & has clinical development plans including NDA submission to CDE in China for CsA Ophthalmic Gel, continuing patient recruitment in P-III study of NVK002 for myopia & launched a clinical study in China for presbyopia
Ref: Businesswire | Image: Pfizer
